NCT05028374View on ClinicalTrials.gov

COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies

PHASE2CompletedINTERVENTIONAL

Enrollment

119

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

November 2, 2021

Study Completion Date

November 2, 2021

Conditions

Multiple MyelomaAL AmyloidosisChronic Lymphocytic Leukemia

Interventions

DRUG

"A single booster dose of the Moderna mRNA COVID-19 vaccine"

All participants will receive a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly. This is an open label, non-randomized trial.

Trial Locations (1)

48201

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT05028374 - COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies | Biotech Hunter | Biotech Hunter